Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Sortiert nach
Open Access
    Datensatz exportieren als...
  • BibTeX
Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
Therapeutic advances in neurological disorders, 2017-10, Vol.10 (10), p.343-359
2017
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
How to reduce the delay of diagnosing secondary progression in multiple sclerosis
Multiple sclerosis, 2021-04, Vol.27 (4), p.646-647
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Natalizumab during pregnancy and lactation
Multiple sclerosis, 2018-10, Vol.24 (12), p.1627-1634
2018
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors
Multiple sclerosis, 2013-11, Vol.19 (13), p.1792-1799
2013
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Assessing the immune response to SARS-CoV-2 mRNA vaccines in siponimod-treated patients: a nonrandomized controlled clinical trial (AMA-VACC)
Therapeutic advances in neurological disorders, 2022-01, Vol.15, p.175628642211353-17562864221135305
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
The need for a strategic therapeutic approach: multiple sclerosis in check
Therapeutic Advances in Chronic Disease, 2022-01, Vol.13, p.20406223211063032-20406223211063032
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey
Therapeutic advances in neurological disorders, 2016-07, Vol.9 (4), p.250-263
2016
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review
Therapeutic Advances in Neurological Disorders, 2022-01, Vol.15, p.175628642211331-17562864221133163
2022
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”
Multiple sclerosis, 2020-05, Vol.26 (6), p.741-742
2020
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study
Multiple sclerosis, 2020-11, Vol.26 (13), p.1729-1739
2020
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286420982134-1756286420982134
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
Multiple sclerosis, 2022-06, Vol.28 (7), p.1131-1137
2022
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis
Multiple sclerosis, 2022-04, Vol.28 (4), p.608-619
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Differential effects of selective versus unselective sphingosine 1-phosphate receptor modulators on T- and B-cell response to SARS-CoV-2 vaccination
Multiple sclerosis, 2023-12, Vol.29 (14), p.1849-1859
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Multiple sclerosis, 2022-04, Vol.28 (5), p.842-846
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Letter to the editor on the paper: “The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”
Multiple sclerosis, 2018-05, Vol.24 (6), p.820-822
2018
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
Multiple sclerosis, 2020-01, Vol.26 (1), p.48-56
2020
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study
Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286421993999-1756286421993999
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany
Therapeutic advances in neurological disorders, 2018-01, Vol.11, p.1756285617748845-1756285617748845
2018
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
Multiple sclerosis, 2018-09, Vol.24 (10), p.1337-1346
2018
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Gender disparities in health resource utilization in patients with relapsing–remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients
Therapeutic advances in neurological disorders, 2020, Vol.13, p.1756286420960274-1756286420960274
2020
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study
Multiple sclerosis, 2023-12, Vol.29 (14), p.1795-1807
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
Therapeutic advances in neurological disorders, 2023-01, Vol.16, p.17562864231194823-17562864231194823
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
Journal of Central Nervous System Disease, 2019, Vol.11, p.1179573519831997
2019
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
Multiple sclerosis, 2020-11, Vol.26 (13), p.1719-1728
2020
Volltextzugriff (PDF)
1 – 25 von 51
Suche als RSS-Feed
Aktive Filter
PublikationsformBerichte
KollektionSAGE Publications
Suchergebnisse filtern
Filter anzeigen